Clinical trials: Human Papillomavirus (HPV)-Related Cervical Cancer
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV.
- Conditions
- AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
- Trial name
- COVENANT (NCT03284866)
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Saline
- Where
- 6 sites in Kenya, Malawi and 3 more
- Volunteers
- 535 people
- Sponsor
- AIDS Malignancy Consortium
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Carcinoma, Squamous Cell, Head and Neck Neoplasms
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
The purpose of this research study is to learn about the effectiveness of using lower-intensity radiation and chemotherapy to treat human papillomavirus (HPV) associated low-risk oropharyngeal and/or unknown primary squamous cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT01530997
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01932697
- Testing
- Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Oropharyngeal Neoplasms
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
This clinical trial studies the intensity of adjuvant ("helper") therapy required in p16 positive oropharynx cancer patients, who have had all known disease removed surgically by a minimally invasive approach, and who have…
- Trial name
- ADEPT (NCT01687413)
- Testing
- Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Human Papillomavirus-Related Cervical Carcinoma
Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
This phase IIIb trial compares a single dose of the Cervarix vaccine in girls to 3 doses of the Gardasil vaccine in young women for the prevention of human papillomavirus (HPV) infection.
- Trial name
- PRIMAVERA (NCT03728881)
- Testing
- Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine
- Where
- Costa Rica
- Volunteers
- 1,240 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer.
- Trial name
- NCT04580446
- Testing
- Hypofractionated intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Uterine Cervical Neoplasm, Uterine Neoplasms
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
The Self-Testing options in the Era of Primary HPV screening for cervical cancer (STEP) trial will evaluate effectiveness of home-based HPV kits for improving cervical cancer screening uptake and its cost-effectiveness.
- Conditions
- Uterine Cervical Neoplasm, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
- Trial name
- STEP (NCT04679675)
- Testing
- Usual Care, Education, Direct Mail
- Where
- United States
- Volunteers
- 32,771 people
- Sponsor
- Kaiser Permanente
Carcinoma, Squamous Cell, Head and Neck Neoplasms
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
The purpose of this research study is to learn about the effectiveness of using lower-intensity radiation and chemotherapy to treat human papillomavirus (HPV) associated low-risk oropharyngeal and/or unknown primary squamous cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT02281955
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 5 sites in United States
- Volunteers
- 115 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
This phase II trial studies how well ipilimumab works in treating patients with human papilloma virus (HPV)-related cervical cancer that has come back or that has spread to other areas of the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma
- Trial name
- NCT01693783
- Testing
- Ipilimumab, Laboratory Biomarker Analysis
- Where
- 13 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus, Squamous Cell Carcinoma
De-Escalation Therapy for Human Papillomavirus Negative Disease
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the…
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma
- Trial name
- DEPEND (NCT03944915)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago